Erbitux as a milestone in the cancer therapy to launch in Korea.

Published: 2006-05-03 06:56:00

Updated: 2006-05-03 06:56:00

Merck Korea, a subsidiary of German Merck, launched Erbitux (Cetuximab), a new dimensional anti-cancer drug, into Korean markets on April 28 for the treatment of patients with spreaded colon cancer who are positive with EGF receptors but not responded to Irinotecan and other conventional chemotherapy. The company got the KFDA approval in June 2005.

In the ceremonial meeting on April 28, pro...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.